1.68%
7.29%
11.89%
-3.63%
34.43%
-43.17%
106.83%
AI Spotlight on ALIF
Company Description
AddLife AB (publ), together with its subsidiaries, provides equipment, medical devices, and reagents primarily to healthcare system, research, colleges, and universities, as well as the food and pharmaceutical industries.The company operates in two segments, Labtech and Medtech.The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory equipment for haematology, pathology, point-of-care diagnostics, cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, consumables, and analytical instruments segments.
This segment also offers support, maintenance, advice, and training services.The Medtech segment provides medical device products for surgery, respiration, intensive care, wound care, enteral nutrition, fall prevention, welfare technology, ear, and nose and throat segments, as well as bathroom-related assistive devices and assistive devices for children with disabilities.It operates in Sweden, Finland, Denmark, Norway, the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, rest of Europe, and internationally.
AddLife AB (publ) was founded in 1906 and is based in Stockholm, Sweden.
Market Data
| Last Price | 151.5 |
| Change Percentage | 1.68% |
| Open | 149.3 |
| Previous Close | 149 |
| Market Cap ( Millions) | 17770 |
| Volume | 85510 |
| Year High | 169.8 |
| Year Low | 94.65 |
| M A 50 | 137.71 |
| M A 200 | 138.6 |
Financial Ratios
| FCF Yield | 3.76% |
| Dividend Yield | 0.66% |
| ROE | 2.30% |
| Debt / Equity | 106.07% |
| Net Debt / EBIDTA | 386.62% |
| Price To Book | 3.6 |
| Price Earnings Ratio | 157.8 |
| Price To FCF | 26.56 |
| Price To sales | 1.77 |
| EV / EBITDA | 17.15 |
News
- Jan -23 - Exploring 3 Undervalued Small Caps With Insider Buying Across Global Markets
- Oct -24 - AddLife AB (FRA:1AD1) Q3 2024 Earnings Call Highlights: Strategic Moves and Market Challenges
- Oct -09 - AddLife AB (FRA:1AD1) (Q2 2024) Earnings Call Highlights: Strong Growth and Strategic ...
- Jul -19 - Exploring Undervalued Small Caps With Insider Actions In July 2024
- Jul -18 - Exploring Three Undervalued Small Caps With Insider Action In The Market
- Jul -16 - Exploring Undervalued Small Caps With Insider Buying In July 2024
- Jul -12 - July 2024 Insight On Undervalued Small Caps With Insider Buying In The Region
- Jul -08 - Exploring Undervalued Small Caps With Insider Insights In July 2024
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> MedTech
Expected Growth : 7 %
What the company do ?
MedTech from AddLife AB (publ) is a Swedish life science company that develops and provides medical technologies and products for healthcare and medical research.
Why we expect these perspectives ?
MedTech from AddLife AB (publ) achieves 7% growth driven by increasing demand for innovative medical devices, strategic acquisitions, and expansion into new markets. Additionally, investments in R&D, digitalization, and regulatory compliance contribute to the segment's growth. Furthermore, the aging population and rising healthcare expenditure also fuel the demand for MedTech products and services.
Segment n°2 -> LabTech
Expected Growth : 5 %
What the company do ?
LabTech is a Swedish company acquired by AddLife AB, providing laboratory equipment and consumables for life science research and diagnostics.
Why we expect these perspectives ?
LabTech's 5% growth is driven by increasing demand for laboratory equipment and services, expansion into new markets, and strategic acquisitions. Additionally, investments in R&D and digitalization enable the company to stay competitive, while a strong sales network and customer relationships contribute to steady revenue growth.
Segment n°3 -> Group Items
Expected Growth : 4 %
What the company do ?
Group Items from AddLife AB (publ) refers to the categorization of products or services into distinct groups, enabling efficient management and analysis of business operations.
Why we expect these perspectives ?
AddLife AB's 4% growth is driven by increasing demand for healthcare technology and services, expansion into new markets, strategic acquisitions, and a strong focus on innovation and R&D. Additionally, the company's diversified portfolio and cost-effective solutions contribute to its growth momentum.
Addlife Ab (Publ) Products
| Product Range | What is it ? |
|---|---|
| Lab Equipment | AddLife AB provides a range of laboratory equipment, including microscopes, spectrophotometers, and centrifuges, designed to support life science research and development. |
| Molecular Diagnostics | AddLife offers molecular diagnostic solutions, including PCR instruments and reagents, for the detection and analysis of genetic material. |
| Bioprocessing | AddLife provides bioprocessing solutions, including bioreactors and fermentation systems, for the development and production of biopharmaceuticals. |
| Medical Imaging | AddLife offers medical imaging solutions, including MRI and CT scanners, for diagnostic and research applications. |
| In Vitro Diagnostics | AddLife provides in vitro diagnostic solutions, including immunoassay systems and reagents, for the detection and monitoring of diseases. |
AddLife AB (publ)'s Porter Forces
Threat Of Substitutes
AddLife AB (publ) operates in the life science industry, which is characterized by a moderate threat of substitutes. While there are some alternative products and services available, they are not perfect substitutes, and the company's products and services have a unique value proposition.
Bargaining Power Of Customers
AddLife AB (publ) has a diverse customer base, and no single customer accounts for a significant portion of its revenue. This reduces the bargaining power of customers, as they do not have significant negotiating power.
Bargaining Power Of Suppliers
AddLife AB (publ) has a moderate dependence on its suppliers, particularly for raw materials and equipment. While the company has some negotiating power, suppliers also have some bargaining power due to the specialized nature of the products and services.
Threat Of New Entrants
The life science industry has high barriers to entry, including significant capital requirements, regulatory hurdles, and the need for specialized expertise. This makes it difficult for new entrants to enter the market, reducing the threat of new entrants.
Intensity Of Rivalry
The life science industry is highly competitive, with many established players competing for market share. AddLife AB (publ) faces intense competition from other companies, which can lead to pricing pressure and reduced market share.
Strength
Weaknesses
Opportunities
Threats
Capital Structure
| Value | |
|---|---|
| Debt Weight | 49.92% |
| Debt Cost | 9.21% |
| Equity Weight | 50.08% |
| Equity Cost | 10.13% |
| WACC | 9.67% |
| Leverage | 99.68% |
AddLife AB (publ) : Quality Control
AddLife AB (publ) passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| TDVOX.ST | Tobii Dynavox AB (Publ) develops and sells assistive technology products for communication in Sweden and internationally. The company provides technology and solutions for augmentative and alternative communication for people with … |
| SKAN.SW | SKAN Group AG provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Asia, Europe, the Americas, and internationally. It operates in two segments: Equipment and Solutions … |
| SFL.MI | Safilo Group S.p.A. engages in the design, production, wholesale, and retail distribution of products for the eyewear market in North America, Europe, the Asia Pacific, and internationally. Its brand portfolio … |
| CLTN.SW | COLTENE Holding AG develops, manufactures, and sells disposables, tools, and equipment for dentists and dental laboratories in Europe, the Middle East, Africa, North America, Latin America, and Asia/Oceania. It offers … |
| AMS.L | Advanced Medical Solutions Group plc, together with its subsidiaries, designs, develops, manufactures, and distributes products for the wound care, surgical, and wound closure markets in the United Kingdom, Germany, France, … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
SKAN
A-Score
1-Year Total Return ->
🥈
AddLife
A-Score
1-Year Total Return ->
🥉
Coltene
A-Score
1-Year Total Return ->
4
Advanced Medical Solutions
A-Score
1-Year Total Return ->
5
Safilo
A-Score
1-Year Total Return ->
6
